Recently Featured

Cosmo Pharma Eyes 2027 NDA for Baldness Candidate After Positive Phase III 12-Month Data

May 3, 2026
Cosmo Pharmaceuticals has announced its intention to file for FDA approval of clascoterone 5% topical solution for androgenetic alopecia (AGA) by early 2027, following promising 12-month Phase III data demonstrating significant hair growth and a favorable safety profile for long-term use. This data supports the drug’s potential as a viable treatment for a condition that…

Utah Expands AI Integration in Healthcare Beyond Prescription Refills

May 3, 2026
Utah has made significant strides in healthcare innovation by permitting the startup Doctronic to utilize artificial intelligence for prescription refills, a move that has garnered considerable attention in the industry. This initiative is not merely a standalone effort; it reflects a broader strategy by the state to integrate AI technologies across various healthcare sectors, enhancing…

Merck’s fast-ascending kidney cancer drug hits a setback

May 2, 2026
Merck’s Welireg has encountered a significant setback in its clinical development for first-line kidney cancer treatment, as recent trial results failed to meet efficacy benchmarks. This outcome not only eliminates a promising blockbuster opportunity for Merck but also opens the door for competitors, particularly Arcus Biosciences, which is advancing its own kidney cancer therapy. Analysts…

Alcami to Acquire Contract Packaging Organization Tjoapack

May 2, 2026
Alcami Corporation recently announced it has entered into a definitive agreement to acquire Tjoapack, a leading global contract packaging organization with facilities in the United States and The Netherlands. This acquisition signifies Alcami’s strategic move to enhance its operational footprint in Europe, marking a pivotal step in its growth trajectory. Tjoapack has been a trusted…

Ongoing Cases